RxDoctor Payments DataLook up a doctor →

Felix Dailey-Sterling, MD

Cardiovascular Disease · Guttenberg, NJNPI 1194720540

Payments from drug & device makers

$567,623in general payments, 2019–2025

Across 1,497 payments — averaging $379.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$252K
  • Boehringer Ingelheim$91K
  • Amgen$74K
  • Johnson & Johnson$52K
  • Amarin Pharma, Inc.$25K
  • AstraZeneca$13K
  • plus $61K from 36 others

What the payments were for

  • Consulting fees$6,1201%
  • Speaking & faculty fees$485,85786%
  • Travel & lodging$33,8416%
  • Food & beverage$41,7717%
  • Education$330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$567,623 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$201,479
Medicare patients
422
Services billed
1,534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide416$503,735
JardianceEmpagliflozin480$448,399
EliquisApixaban350$307,524
EntrestoSacubitril/Valsartan306$301,684
XareltoRivaroxaban200$190,875
FarxigaDapagliflozin Propanediol192$167,077
Repatha SureclickEvolocumab197$124,425
VascepaIcosapent Ethyl146$88,201
BrilintaTicagrelor78$43,404
Icosapent Ethyl60$20,019
RybelsusSemaglutide17$18,007
MounjaroTirzepatide18$17,899
TrulicityDulaglutide15$15,546
CorlanorIvabradine Hcl24$14,695
EdarbyclorAzilsartan Med/Chlorthalidone27$14,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$252,460$521,742433 claims
Boehringer IngelheimJardiance$90,548$448,399480 claims
PfizerEliquis$8,622$307,524350 claims
NovartisEntresto$11,227$301,684306 claims
AstraZenecaFarxiga, Brilinta$12,596$210,482270 claims
Johnson & JohnsonXarelto$51,703$190,875200 claims
Lilly USA, LLCMounjaro, Trulicity$7,648$33,44433 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$45$24,96550 claims
AmgenCorlanor$73,816$14,69524 claims
BayerKerendia$10,559$9,94715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Guttenberg

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →